401 related articles for article (PubMed ID: 25062764)
1. Widespread heterogeneous neuronal loss across the cerebral cortex in Huntington's disease.
Nana AL; Kim EH; Thu DC; Oorschot DE; Tippett LJ; Hogg VM; Synek BJ; Roxburgh R; Waldvogel HJ; Faull RL
J Huntingtons Dis; 2014; 3(1):45-64. PubMed ID: 25062764
[TBL] [Abstract][Full Text] [Related]
2. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease.
Thu DC; Oorschot DE; Tippett LJ; Nana AL; Hogg VM; Synek BJ; Luthi-Carter R; Waldvogel HJ; Faull RL
Brain; 2010 Apr; 133(Pt 4):1094-110. PubMed ID: 20375136
[TBL] [Abstract][Full Text] [Related]
3. Symptom heterogeneity in Huntington's disease correlates with neuronal degeneration in the cerebral cortex.
Mehrabi NF; Waldvogel HJ; Tippett LJ; Hogg VM; Synek BJ; Faull RL
Neurobiol Dis; 2016 Dec; 96():67-74. PubMed ID: 27569581
[TBL] [Abstract][Full Text] [Related]
4. Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease.
McColgan P; Seunarine KK; Razi A; Cole JH; Gregory S; Durr A; Roos RA; Stout JC; Landwehrmeyer B; Scahill RI; Clark CA; Rees G; Tabrizi SJ;
Brain; 2015 Nov; 138(Pt 11):3327-44. PubMed ID: 26384928
[TBL] [Abstract][Full Text] [Related]
5. Increased brain tissue sodium concentration in Huntington's Disease - a sodium imaging study at 4 T.
Reetz K; Romanzetti S; Dogan I; Saß C; Werner CJ; Schiefer J; Schulz JB; Shah NJ
Neuroimage; 2012 Oct; 63(1):517-24. PubMed ID: 22796981
[TBL] [Abstract][Full Text] [Related]
6. Cortical interneuron loss and symptom heterogeneity in Huntington disease.
Kim EH; Thu DC; Tippett LJ; Oorschot DE; Hogg VM; Roxburgh R; Synek BJ; Waldvogel HJ; Faull RL
Ann Neurol; 2014 May; 75(5):717-27. PubMed ID: 24771513
[TBL] [Abstract][Full Text] [Related]
7. New Perspectives on the Neuropathology in Huntington's Disease in the Human Brain and its Relation to Symptom Variation.
Waldvogel HJ; Kim EH; Thu DC; Tippett LJ; Faull RL
J Huntingtons Dis; 2012; 1(2):143-53. PubMed ID: 25063328
[TBL] [Abstract][Full Text] [Related]
8. Cortical and striatal neurone number in Huntington's disease.
Heinsen H; Strik M; Bauer M; Luther K; Ulmar G; Gangnus D; Jungkunz G; Eisenmenger W; Götz M
Acta Neuropathol; 1994; 88(4):320-33. PubMed ID: 7839825
[TBL] [Abstract][Full Text] [Related]
9. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease.
Hedreen JC; Peyser CE; Folstein SE; Ross CA
Neurosci Lett; 1991 Dec; 133(2):257-61. PubMed ID: 1840078
[TBL] [Abstract][Full Text] [Related]
10. Evidence for progression in frontal cortical pathology in late-stage Huntington's disease.
Selemon LD; Rajkowska G; Goldman-Rakic PS
J Comp Neurol; 2004 Jan; 468(2):190-204. PubMed ID: 14648679
[TBL] [Abstract][Full Text] [Related]
11. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
[TBL] [Abstract][Full Text] [Related]
12. Pyramidal cell loss in motor cortices in Huntington's disease.
Macdonald V; Halliday G
Neurobiol Dis; 2002 Aug; 10(3):378-86. PubMed ID: 12270698
[TBL] [Abstract][Full Text] [Related]
13. Regional specificity of brain atrophy in Huntington's disease.
Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E
Exp Neurol; 1998 Dec; 154(2):663-72. PubMed ID: 9878201
[TBL] [Abstract][Full Text] [Related]
14. Selective neurodegeneration, neuropathology and symptom profiles in Huntington's disease.
Waldvogel HJ; Thu D; Hogg V; Tippett L; Faull RL
Adv Exp Med Biol; 2012; 769():141-52. PubMed ID: 23560309
[TBL] [Abstract][Full Text] [Related]
15. Increased cortical recruitment in Huntington's disease using a Simon task.
Georgiou-Karistianis N; Sritharan A; Farrow M; Cunnington R; Stout J; Bradshaw J; Churchyard A; Brawn TL; Chua P; Chiu E; Thiruvady D; Egan G
Neuropsychologia; 2007 Apr; 45(8):1791-800. PubMed ID: 17321554
[TBL] [Abstract][Full Text] [Related]
16. The Neuropathology of Huntington's Disease.
Waldvogel HJ; Kim EH; Tippett LJ; Vonsattel JP; Faull RL
Curr Top Behav Neurosci; 2015; 22():33-80. PubMed ID: 25300927
[TBL] [Abstract][Full Text] [Related]
17. Evolution of brain gray matter loss in Huntington's disease: a meta-analysis.
Lambrecq V; Langbour N; Guehl D; Bioulac B; Burbaud P; Rotge JY
Eur J Neurol; 2013 Feb; 20(2):315-21. PubMed ID: 22925174
[TBL] [Abstract][Full Text] [Related]
18. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
[TBL] [Abstract][Full Text] [Related]
19. Cerebellar degeneration correlates with motor symptoms in Huntington disease.
Singh-Bains MK; Mehrabi NF; Sehji T; Austria MDR; Tan AYS; Tippett LJ; Dragunow M; Waldvogel HJ; Faull RLM
Ann Neurol; 2019 Mar; 85(3):396-405. PubMed ID: 30635944
[TBL] [Abstract][Full Text] [Related]
20. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
